January 30, 1996
Syncor International Corp. said it will make a $14-million investment in the development and distribution of a new type of diagnostic tool for detecting lung and breast cancer over the next three years. The product, called positron emission tomography, is an extension of the kind of radio-pharmaceutical product the company already sells. Syncor expects to set up 24 distribution centers for it nationwide.
October 28, 1997
Syncor International Corp. said it signed a five-year sole-source contract with AmeriNet Inc. to supply unit dose and bulk radiopharmaceuticals on a national basis. The Chatsworth-based pharmaceuticals firm said that the agreement has a potential value of $210 million. St. Louis-based AmeriNet is one of the largest group purchasing organizations in the nation with more than 7,100 members in all 50 states making more than $3.5 billion in purchases annually.
March 19, 1996
Syncor International Corp. posted a profit turnaround in the fourth quarter, while its net income for all of 1995 nearly quadrupled compared to 1994. The Chatsworth-based company posted net income of $1.13 million in the fourth quarter, compared to a $537,000 loss a year earlier. Syncor's sales in the fourth quarter rose 4% to $85.1 million, compared to $81.7 million a year earlier. For all of 1995, Syncor saw its net income jump to $4.7 million, compared to $1.
October 31, 1995
Syncor International Corp., a Chatsworth operator of nuclear pharmacies, said its profit for the third quarter that ended Sept. 30 was $1.2 million, compared to a loss of $1.1 million for the same period of 1994. Sales for the third quarter decreased slightly to $81 million, down from $81.6 million a year earlier. For the first nine months of this year, the profit was $3.5 million, more than doubling the year-earlier figure of $1.7 million. Sales for the nine months grew by 4% to $247.
December 28, 1993
Syncor International Corp., a Chatsworth provider of specialty pharmaceutical services, said its fiscal second-quarter profit surged 35% to $2.85 million, from $2.11 million a year earlier. For the quarter that ended Nov. 30, the company's revenue rose 8% to $61.2 million, from $56.9 million a year earlier. Syncor attributed the improved results partly to its recent strategic alliance with its principal supplier of radiopharmaceuticals, DuPont Merck Pharmaceutical Co.
September 27, 1994
Syncor International Corp., a Chatsworth-based supplier of nuclear pharmaceutical products, said it expects to post a loss for the quarter ending Sept. 30. It cited cost-cutting pressures in the health care industry, stemming from managed health-care providers, as a cause of the loss. Syncor said it will report a loss of about $1 million on revenues of about $80 million for the quarter. In the three-month period a year earlier, the company earned $3 million on sales of $60.4 million.